Key facts
- Emerging Therapy Solutions’s last known valuation is $18.0M (Jun 2021).
- It has raised $23.3M across 7 recorded rounds; the latest was Early Stage VC ($5.0M) in Mar 2024.
- Notable investors include Telegraph Hill Partners.
- Emerging Therapy Solutions has filed 7 Form Ds with the SEC since 2019, most recently Mar 2024 ($5.0M sold to 5 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 7 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Emerging Therapy Solutions
Funding rounds
7 roundsAbout Emerging Therapy Solutions
Developer of a predictive intelligence platform designed to outsource the management of cell and gene therapy treatments for healthcare payers. The company's platform provides patient management data collection, analysis, reporting, claims administration, and supply chain management, enabling healthcare providers to streamline the management of complex, emerging therapy treatments.
- Sector
- Healthcare
- HQ
- Bloomington, MN, United States
- Founded
- 2018
- Employees
- 39
- Website
- emergingtherapies.com/
- Ownership
- Privately Held (backing)
Emerging Therapy Solutions doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Emerging Therapy Solutions shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Emerging Therapy Solutions in its N-PORT filings yet. We sweep new filings monthly.